Millennium Labs – Prescription Drug Monitoring & Genetic Testing



Press Releases


1 2 3 4

Millennium Laboratories and RxAnte Link Strategic Advisory Boards

Advisors include industry experts, such as Former Senate Majority Leader Tom Daschle and former CMS Administrator Dr. Mark McClellan, with goal of advancing medication management

SAN DIEGO (April 3, 2014)– Millennium Laboratories announced today that it has established an advisory board consisting of distinguished health care, technology and public policy experts to provide strategic guidance to the company.  An established leader in the science of medication monitoring and pharmacogenetic testing, Millennium assembled the advisory board in an effort to further support company goals.

The announcement comes on the heels of the RxAnte acquisition, a health care predictive analytics and decision support company that improves population-level medication adherence. RxAnte is simultaneously extending relationships with two of its key advisors.

“We are proud to have the honor of working with such esteemed experts to contribute to our vision of improving quality of care and reducing waste in the system,” said Brock Hardaway, CEO of Millennium Laboratories. “The guidance from these advisors, coupled with our recent acquisition of RxAnte, ultimately will help patients and physicians achieve better results through more personalized, effective treatments.”

“Our advisors have had a significant and positive influence on RxAnte’s products and services—and by extension, on the members and patients our clients serve,” said Josh Benner, President of RxAnte. “Our entire team is excited to build on our relationship with these key individuals.”

The companies anticipate joint meetings of their advisors, to build on their respective foundations in medication monitoring and advanced analytics. This, in turn, will help the companies develop innovative technologies, products and services to address payer, provider, and patient needs today and in the future.

New members of the Advisory Board include:

    • • Senator Tom Daschle, a senior policy advisor in DLA Piper’s Government Affairs practice. Sen. Daschle has participated in the development and debate of many major public policy issues of the last three decades. He is one of the longest serving Senate Democratic leaders in history and the only one to serve twice as both Majority and Minority Leader. He distinguished his experience in health care through the publication of “Critical: What We Can Do About the Health Care Crisis” and “Getting It Done: How Obama and Congress Finally Broke the Stalemate to Make Way for Health Care Reform.”

      He is the Chair of the DuPont Advisory Committee on Agriculture Innovation and Productivity, as well as the BP Tangguh Independent Advisory Panel. He also serves on the Health Policy and Management Executive Council at the Harvard School of Public Health, and is a member of the Council on Governance for Sustainability at the World Economic Forum and the Federal Advisory Board of Accenture.

    • • John Short, principal of Short Consulting LLC, a health care consulting firm. Dr. Short is also the former CEO of RehabCare Group, a rehabilitation services provider that was acquired by Kindred Health Care in 2011, and board member for WellPoint and its subsidiary CareMore. He started his first health care consulting firm nearly 45 years ago. Dr. Short serves on the Board of Directors of InteliStaf Holdings Inc., and is a member of the Board of Acute Long Term Hospital Association (ALTHA). He was formerly a member of the American Hospital Association’s Post-Acute Presidents Forum, and was the managing partner of Phase 2 Consulting, serving large acute care health systems throughout the United States.

RxAnte advisors continuing their service on the Advisory Board include:

  • • Dr. Mark B. McClellan, a senior fellow and director of the Health Care Innovation and Value Initiative at the Brookings Institution. Dr. McClellan is a former administrator of the Centers for Medicare & Medicaid Services (CMS) and former commissioner of the U.S. Food and Drug Administration (FDA), where he developed and implemented major reforms in health policy. He is the founding chairman of the FDA’s Reagan-Udall Foundation, is co-chair of the Quality Alliance Steering Committee, leads the National Quality Forum’s partnership on applying clinician quality measures, is a member of the Institute of Medicine, and is a research associate at the National Bureau of Economic Research. Dr. McClellan previously served as a member of the President’s Council of Economic Advisers, senior director for health care policy at the White House, and also advises U.S. government officials on health care policy issues. A physician and economist by training, he also has a highly distinguished record in public service and in academic research.

  • • Robert Pfotenhauer, MPH, the former CEO of four healthcare companies with more than 35 years of experience in health insurance and health care delivery. He began his career with Group Health Cooperative of Puget Sound in Seattle and in his final role, helped build the nation’s leading Part D prescription drug company of United Health Group, serving more than 4.5 million Medicare members. He has also held executive roles with Group Health Association, Kaiser Permanente and VISICU.

About Millennium Laboratories and RxAnte
Millennium Laboratories, a leader in the science of medication monitoring and pharmacogenetic testing, is transforming the way health care professionals monitor and manage their patients’ medication therapy. Through the use of advanced technology, supported by research and education, Millennium helps practitioners personalize care for patients. More information can be found at www.millenniumlabs.com.

RxAnte helps large healthcare organizations improve prescription drug use. The RxAnte System™ is a patent-pending analytics platform that includes predictive and decision analytics, advanced evaluation methods, and an innovative, cloud-based platform that equips health care professionals to improve medication outcomes for at-risk patients.  More information is available at www.RxAnte.com

Millennium Labs Helps Launch Coalition to Tackle Prescription Drug Misuse, Abuse in San Diego

Initial focus is thefts at real estate open houses

SAN DIEGO (March 11, 2014) – The Greater San Diego Association of REALTORS®, local nonprofits, Millennium Laboratories, and other partners announced today the formation of the Safe Homes Coalition that will work to inform people about the proper use, storage and disposal of prescription drugs.

San Diego County District Attorney Bonnie Dumanis and San Diego County Sheriff Bill Gore voiced strong support for the coalition, which representatives said was a response to reports of prescription drug thefts during real estate open houses.

Prescription drug abuse continues to take a toll in San Diego County as the San Diego County Prescription Drug Abuse Task Force reported last November. According to the task force, deaths from prescription drug overdoses have increased sharply over the last five years, as have prescription drug-related visits to hospital emergency departments. Especially alarming was the effect of the epidemic on youth with nearly 20 percent of 11th-graders in San Diego County reporting that they had experimented with prescription drugs. Real estate open houses remain a source of those prescription drugs.

“The reports of young people removing prescription medications from open houses made it apparent that real estate professionals can be the first line of defense in preventing such thefts of these medications,” Gore said at a coalition press conference.

The region’s 12,000-plus REALTORS® will play a key role in a multi-faceted coalition campaign designed to raise awareness of, and help, combat the problem. Millennium Laboratories, nonprofit Mental Health Systems, its North Inland Community Prevention Program, Oakwood Escrow, nonprofit Hope2Gether Foundation, and the San Diego County Prescription Drug Abuse Task Force are the coalition’s other members.

The group shared a public service announcement to be aired on local television and radio stations. The coalition also plans to distribute 10,000 bags to be used by homeowners to secure prescription medications prior to open houses in San Diego. The bags will be distributed through seven REALTORS® service centers in the county. Outreach via presentations and materials to real estate professionals and a Facebook page with information about prescription drug abuse and ways to counter it are also part of the campaign.

The campaign will highlight proper disposal options for prescription medications. Those include national Take Back Days like the one coming up April 26, and drop boxes that are available year-round at every sheriff station in the county.

“Prescription drug abuse is the leading cause of unintended deaths in San Diego County,” Dumanis said. “That’s why we need as many groups as possible working to curtail abuse and misuse. I commend the work of the Safe Homes Coalition in their effort to limit youth access to prescription drugs.”

Although the coalition’s initial focus is San Diego County, the group hopes to expand its campaign through collaborations in targeted communities, throughout California, and across the United States.

To view the Safe Homes Coalition’s PSA go to: http://bit.ly/safehomesPSA. The coalition’s Facebook page is at www.facebook.com/safehomescoalition. Call (858) 391-9303 for information.

Event photos are available upon request.

About Millennium Laboratories
Millennium Laboratories, a leader in the science of medication monitoring and pharmacogenetic testing, is transforming the way health care professionals monitor and manage their patients’ medication therapy. Through the use of advanced technology, supported by research and education, Millennium helps practitioners personalize care for patients. More information can be found at www.millenniumlabs.com.

Contact:
Nicole Beckstrand
Millennium Laboratories
858-217-1192
Nicole.beckstrand@millenniumlabs.com

Massachusetts Federal Court Again Dismisses Whistleblower Lawsuit Against Millennium Laboratories

Millennium, gratified by the final ruling, continues to lead industry initiatives to implement higher compliance standards and ethical business practices

SAN DIEGO (Jan. 30, 2014)— U.S. District Judge Rya Zobel ordered the complete dismissal of a whistleblower suit brought by a former Calloway Laboratories’ senior officer against Millennium Laboratories, a leader in the science of medication monitoring and pharmacogenetic testing. Although the Department of Justice had repeatedly asserted that it would not intervene in the lawsuit, and consented to the suit’s initial dismissal in 2012, the civil suit continued for nearly two years. By entering final judgment in Millennium’s favor and foreclosing any further amendment, the court closes a case that has been funded and used by Millennium’s competitors in efforts to gain advantage in the marketplace.

After five years of litigation, Judge Zobel, in dismissing the whistleblower complaint, wrote that it set forth “no facts describing the circumstances of any unnecessary testing, or the dates when such occurred, or the amounts and dates of any improper claims” and “no allegations of an agreement between defendant and any physician to defraud the government.” 

Millennium has led a series of initiatives to address industry-wide ethical practices, including providing an unrestricted grant to Dr. Richard Payne of Duke University for the purpose of convening drug testing laboratories and other stakeholders to establish voluntary ethical business practices that meet or exceed federal and state regulations. The outcome of that effort will be announced in February. Millennium has also engaged prominent fraud, abuse, and compliance experts, including Lewis Morris, chief counsel to the HHS Office of Inspector General from 2002-2012, and Dick Kusserow of Strategic Management Systems, a former HHS Inspector General, to examine the company’s comprehensive compliance program and evaluate its adherence to OIG’s Compliance Program Guidance for Clinical Laboratories. Millennium’s Compliance Policy is available at www.millenniumlabs.com.

About Millennium Laboratories
Millennium Laboratories, a leader in the science of medication monitoring and pharmacogenetic testing, is transforming the way health care professionals monitor and manage their patients’ medication therapy. Through the use of advanced technology, supported by research and education, Millennium helps practitioners personalize care for patients. More information can be found at www.millenniumlabs.com.

Contact:
Nicole Beckstrand
Millennium Laboratories
858-217-1192
Nicole.beckstrand@millenniumlabs.com

Millennium Laboratories Announces Strategic Acquisition of RxAnte

Advanced analytics technology adds population drug therapy management and predictive capabilities to medication monitoring and pharmacogenetics for optimizing medication outcomes.

SAN DIEGO and McLEAN, VA. (Jan. 13, 2014) —Millennium Laboratories, a leader in the science of medication monitoring and pharmacogenetic testing, announced today its acquisition of RxAnte, a health care predictive analytics and decision support company that improves population-level medication adherence on behalf of health plans, pharmacy benefit management companies, pharmacy chains, and health care providers. Terms of the transaction were not disclosed.

The acquisition will link two rapidly growing health care technology companies that share a strong commitment to improving the safe and effective use of prescription medications through personalized, technology-enabled drug therapy management solutions.

Millennium currently offers medication monitoring using urine drug testing (UDT) and pharmacogenetic testing (PGT) to health professionals treating, pain, substance use disorders, psychiatric disorders, and other chronic diseases. RxAnte is a venture-backed digital health care start-up launched in 2011 and based in the Washington, DC area. Investors in RxAnte included Aberdare Ventures and the West Health Investment Fund. Allen & Company LLC served as financial advisor to RxAnte in connection with this transaction.

RxAnte, whose predictive analytics and decision support platform now manages the medication adherence of over 8 million unique patients, will operate as a wholly owned subsidiary of Millennium. The company’s suite of products for payers and health care providers identifies patients at risk of avoidable costs due to improper medication use or non-adherence and then recommends specific steps for practitioners, pharmacists, and other members of the care team to support at-risk patients.

“Improving medication adherence is increasingly recognized as one of the biggest opportunities to improve patient outcomes and quality of care while slowing the growth of health care costs,” said Millennium’s CEO, Brock Hardaway. “The acquisition of RxAnte represents an exciting step for Millennium in continuing to pursue its strategic vision to improve care quality and health outcomes.”

RxAnte Founder and President, Josh Benner, said, “Payers and providers have strong, new incentives to help their patients get the most from their prescription medicines. What these organizations need now are the tools to help them target and tailor the right treatments and behavioral support to each patient. Together, RxAnte and Millennium offer a robust set of solutions for accomplishing exactly that.”

Beyond continuing to grow their respective core businesses, Millennium and RxAnte also plan to collaborate on new products and services to help payers and health care providers further personalize drug therapy management, improve population health, and reduce the avoidable costs of medication misuse. 

About RxAnte
RxAnte is a health technology company with an innovative analytics platform that is transforming how organizations work with health care professionals, care management intervention providers, and patients to improve the use of safe and effective prescription medications. Created by subject matter experts in medication adherence, health IT, and advanced analytics, the RxAnte System™ is a patent-pending platform that includes predictive and decision analytics, advanced evaluation methods, and an innovative platform for provider engagement. Learn more at www.rxante.com.

About Millennium Laboratories
Millennium Laboratories, a leader in the science of medication monitoring and pharmacogenetic testing, is transforming the way health care professionals monitor and manage their patients’ medication therapy. Through the use of advanced technology, supported by research and education, Millennium helps practitioners personalize care for patients. More information can be found at http://millenniumlabs.com/.

Contacts:
Nicole Beckstrand
Millennium Laboratories
858-217-1192
Nicole.beckstrand@millenniumlabs.com

Sovereign Health Group Announces Use of Millennium PGTSM in Psychiatric Treatment

Sovereign Health Group, a California-based behavioral health company, announced the utilization of Millennium PGT to assess the effectiveness of medication in the treatment of psychiatric disorders. Dr. Larry Snyder, Sovereign Health Group medical director, said, “Pharmacogenetic testing raises the level of clinical excellence significantly, giving us an unprecedented level of information about patients and the most effective way of dealing with their issues. Adoption of genetic testing is part of our commitment to rigorous, evidence-based care.” For more information, please read Sovereign Health Group’s press release.

Millennium Laboratories Delivers Comfort, Security, and Joy to San Diego Foster Children and Children in Need

Local company delivers 15,000 stuffed animals to San Diego County at Polinsky Children’s Center

SAN DIEGO (Dec. 17, 2013)—Millennium Laboratories, a leader in the science of toxicology and pharmacogenetics, delivered 15,000 stuffed animals to San Diego County’s foster children and at risk youth at an event on Monday at the Polinsky Children’s Center in Kearny Mesa, Calif. Millennium’s management and employees collected the stuffed animals in the months of November and December, and through this donation and unique partnership, hope to provide the children cared for by various San Diego County organizations with support, courage, and hope during a difficult time in their lives.

“Millennium is excited to partner with the County of San Diego and support programs like the Polinsky Children’s Center, which provides a vital resource to the abused and abandoned children of our community,” said President of Millennium Laboratories, Howard Appel. “This is truly a celebration of the efforts by so many community and government organizations, and we are honored to serve the community in which we live and work.”

At the event, Chairman Greg Cox, County Board of Supervisors and Debra Zanders-Willis, Director, County of San Diego Child Welfare Services, accepted Millennium’s donation of 15,000 stuffed animals collected by management and employees. Video and reporting from this event can be found at: http://countynewscenter.com/video?v=153329.

“We can give a child a teddy bear when they are going through a very stressful situation in their lives. There is nothing like a teddy bear to make people feel a little more warm and fuzzy, particularly for kids,” said Supervisor Cox.

“It is a very generous donation, and very timely. This time of year many of our children are separated from their families, and while the teddy bears can’t replace the nurturing and love that they would get from their families, it certainly offers them comfort and a bright light during this particular season,” said Zanders-Willis.

The Polinsky Children’s Center provides care to thousands of children every year ranging in age from newborn to 18 years, who must be separated from their families for their own safety, or when parents are unable to provide care. This center is San Diego County’s only emergency shelter for children who cannot remain at home as a result of abuse or neglect. On any given day, San Diego has 3,300 children living in the foster care system.[1]

A number of organizations that partner with the County of San Diego to provide services to foster, at risk, and homeless children will also receive stuffed animals as part of this donation. Some of the identified recipients include Straight From The Heart, St. Vincent De Paul Village, and the Armed Services YMCA at Camp Pendleton.

[1] About Promise2Kids. Promise2Kids Web site. http://promises2kids.org/about-us/. Accessed December 16, 2013.

Contact:
Nicole Beckstrand
Millennium Laboratories
858-217-1192
Nicole.beckstrand@millenniumlabs.com


Millennium Laboratories Awarded Testing Agreement with Texas Mutual Insurance Company

Millennium is a preferred provider for medication monitoring and drug detection services in the Texas Star Network®

SAN DIEGO and AUSTIN, Texas (Nov. 18, 2013) —Millennium Laboratories, a leader in the science of toxicology and pharmacogenetics, today announced a test services agreement with Texas Mutual Insurance Company, the leading provider of workers’ compensation insurance in Texas. Millennium Laboratories is now in network with Texas Mutual and will be providing workers’ compensation recipients with its extensive list of medication monitoring and drug detection services.

“Texas Mutual’s priority is to ensure injured workers receive quality care and return to productive employment,” said Kim Haugaard, vice president of network and medical operations at Texas Mutual. “Our partnership with Millennium Laboratories gives us, and network medical providers, another tool for offering personalized care.”

While opioid therapy represents a necessary component in pain management, potential misuse by workers is a major concern for employers, creating unique challenges for payers in this market. As a preferred provider for Texas Mutual, Millennium will provide medication monitoring and drug detection services to practitioners to evaluate patients’ use of prescribed medications and substances. With this objective clinical tool health care providers may be able to safely and effectively monitor and manage their patients’ medication therapy, helping them get back to work and resume productive, quality lives. 

“Our superior medication monitoring and drug detection testing services will enable a better understanding of medications and drugs a patient may or may not be taking, reveal potential drug to drug interactions, and create opportunity for dialogue between physician and patient regarding the treatment plan,” said Millennium Laboratories’ Vice President, Managed Markets and Workers’ Comp, Brent Gibbs. “We are proud to partner with Texas Mutual Insurance to provide better diagnostic tools for their providers and patients.”

About Texas Mutual Insurance Company
Austin-based Texas Mutual Insurance Company is the state’s leading provider of workers’ compensation insurance, with approximately 38 percent of the market. Since 1991, the company has provided a stable, competitively priced source of workers’ comp insurance for Texas employers. Preventing workplace accidents and minimizing their consequences are major parts of Texas Mutual’s mission. For more information, visit www.texasmutual.com.

About Millennium Laboratories
Millennium Laboratories, a leader in the science of toxicology and pharmacogenetics, is transforming the way health care professionals monitor and manage their patients’ medication therapy.  Through the use of advanced technology, supported by research and education, Millennium helps practitioners personalize care for patients. More information can be found at http://millenniumlabs.com/

Contact:
Nicole Beckstrand
Corporate Communications
Millennium Laboratories
858-217-1192
Nicole.beckstrand@millenniumlabs.com

Millennium Laboratories to Host Session at Medicaid Health Plans of America 2013

Session discusses clinical value of urine drug testing and economic impact of opioid abuse

What: Millennium Laboratories, a leader in the science of toxicology and pharmacogenetics, will host a breakfast session entitled: The Economic Impact of Opioid Abuse and Clinical Value to Medication Monitoring at Medicaid Health Plans of America 2013 (MHPA 2013), the country’s largest gathering of Medicaid health plan industry executives, in National Harbor, Md. on Tuesday, Oct. 22. For more information, visit Millennium Laboratories at booth #112.

Who: Angela Huskey, PharmD, CPE, vice president of clinical practice, Millennium Laboratories and research scientist, Millennium Research Institute and Ira Kornbluth, MD, founder of SMART Pain Management will present.

Why: Attendees of the session at MHPA 2013 will gain an understanding of the clinical value of urine drug testing (UDT) as an objective, evidence-based monitoring tool to aid prescribers in identifying potential misuse, abuse or diversion, as part of a multipronged approach. Huskey will present data from an analysis showing a potential net-benefit for urine drug testing in a population of Medicaid patients with pain. Millennium believes this preliminary investigation is the first time that economic data has been used to show the predictive value of UDT and requires additional investigation and validation in coordination with Millennium’s contracted Medicaid providers.

Who Should Attend: Registered MHPA 2013 attendees may attend. Attendance is limited and available on a first come first served basis. Click here to register http://www.mhpa.org/Events/MHPA_2013/. Members of the media may attend this conference free of charge by contacting Joe Reblando, JReblando@mhpa.org.

When: Tuesday, October 22, 7:30 to 8:30 a.m. Breakfast will be served.

Where: Gaylord National Resort & Convention Center, Baltimore Room 1-2, 201 Waterfront St., National Harbor, Md. 20745. For more information, please visit Millennium Laboratories at booth #112.

Contact:
Nicole Beckstrand
Corporate Communications
Millennium Laboratories
858-217-1192
Nicole.beckstrand@millenniumlabs.com

Millennium Laboratories Announces Expanded Test Offering for Synthetic Marijuana

Also known as Spice, illicit substances now easier to detect in urine

SAN DIEGO (Sept. 23, 2013) – Millennium Laboratories, a leader in the science of toxicology and pharmacogenetics, today announced it has expanded its urine drug test (UDT) offering for synthetic marijuana (i.e., synthetic cannabinoids).

Also known as “Spice” or “K2” and referred to as “fake weed,” synthetic cannabinoids are often available in smoke shops and through the Internet. Typically advertised as incense or potpourri and labeled “not for human consumption,” Spice is typically ingested or smoked. Synthetic cannabinoids are functionally similar to delta-9-tetrahydrocannabinol (THC), the primary psychoactive substance in marijuana and  users experience  similar and exaggerated symptoms including altered perception, elevated heart rate and blood pressure, agitation, paranoia, hallucinations, and in some cases, death has been reported1.

In July 2012, the Synthetic Drug Abuse Prevention Act of 2012 was signed into law in the U.S., banning the synthetic compounds commonly found in Spice products, placing them under Schedule I of the Controlled Substances Act2. However, abuse of these compounds continues to be a problem3. Synthetic cannabinoid compounds continue to evolve as those manufacturing and using them specifically look for altered compounds that will evade detection.

Millennium Laboratories introduced a test for Spice in 2011. The company’s scientists, using a unique process, have developed an expanded test for emerging synthetic cannabinoids. This comprehensive urine drug test is now available to health care providers.

“We see the prevalence of this dangerous substance as a major problem in communities across America and we took action to provide a solution for our customers,” said Howard Appel, Millennium Laboratories’ president. “Our research and development team of preeminent clinical and analytical chemists are constantly designing, developing and implementing new assays to ensure health care providers can appropriately monitor and treat their patients.”

Millennium’s medication monitoring and drug detection services ensure that health care professionals can choose tests individually, based on medical necessity, rather than being obligated to use a one-size-fits-all, pre-set panel of tests. The company’s test menu continues to expand, reflecting the most commonly prescribed medications and an ever evolving list of illicit drugs and new-to-market medications.

Millennium Laboratories offers tests for close to 100 medications and drugs and utilizes liquid chromatography tandem mass spectrometry (LC-MS/MS) technology for specific drug identification and quantification. The comprehensive, quantified drug/metabolite specific results are delivered generally within one day from receipt of specimen at the laboratory, giving health care professionals an objective picture of the medications and drugs their patients may or may not have used.

Contact:
Nicole Beckstrand
Corporate Communications
Millennium Laboratories
858-217-1192
Nicole.beckstrand@millenniumlabs.com

(1) Fattore L, Fratta W. Beyond THC: The New Generation of Cannabinoid Designer Drugs. Front Behav Neurosci. 2011;5(60):1-12.

(2) Drug Enforcement Agency (DEA). Schedules of Controlled Substances: Temporary Placement of Three Synthetic Cathinones Into Schedule I.  Available at: http://www.justice.gov/dea/pubs/pressrel/pr102111.html. Accessed September 20, 2013.

(3) Drug Enforcement Administration, Department of Justice. Schedules of controlled substances: Temporary Placement of Three Synthetic Cathinones in Schedule I. Final Order. Microgram Bulletin. 2011 Nov;44(11):72-85. http://www.justice.gov/dea/pr/micrograms/2011/mg1111.pdf. Accessed September 22, 2013.

Millennium Laboratories Offers New Tests Enabling Personalized Psychiatric Care

New objective tests identify medications and patient-specific drug metabolism to assist in safe and effective prescribing

SAN DIEGO (September 16, 2013) – Millennium Laboratories, a leader in the science of toxicology and pharmacogenetics, today announced an expansion of its Millennium UDT (Urine Drug Testing) and PGT (Pharmacogenetic Testing) platforms to further help clinicians individualize the treatment of patients with pain and psychiatric disorders, including substance use disorder, depression, bipolar disorder and schizophrenia. Including these objective tests as part of a clinical assessment could lead to better patient outcomes by optimizing a clinician’s choice of medication, while potentially minimizing risks for side effects and drug-drug interactions. 

Millennium UDT provides specific drug identification by liquid chromatography-tandem mass spectrometry (LC-MS/MS), detecting the presence of substances and medications in urine. Expansion of the Millennium UDT platform includes the detection of commonly prescribed antidepressants, antipsychotics, antagonists and stimulant medications.

The Millennium PGT platform detects genetic variations in enzymes that may affect the metabolism of certain medications, helping to predict how an individual may respond to those medications. The expansion of Millennium PGT focuses on detecting specific genetic variants, which may affect a patient’s response or ability to tolerate certain psychotropic medications. Millennium PGT now includes testing and personalized interpretation for 24 medications in eight different medication classes including antipsychotics, antidepressants, opioids, benzodiazepines and attention deficit hyperactivity disorder (ADHD) treatments. To see the full list of test offerings, visit www.milleniumlabs.com.

“Failure to take a prescribed therapeutic regimen can lead to relapse, adverse events and hospitalizations, so it’s critical for practitioners to know what medications their patients are taking. The combination of Millennium UDT and PGT in the treatment of patients with psychiatric disorders provides comprehensive information that may improve a clinician’s ability to determine the most appropriate and effective treatment regimen and gauge whether patients are adhering to their regimen,” said Steven Passik, Ph.D., Millennium Laboratories’ director of clinical addiction research and education.

Mental illness is surprisingly common and causes substantial burden to patients, their families and the health care system. It is the leading cause of disability in North American adults, and neuropsychiatric disorders, which include mental illness and substance use disorders, are more significant contributors to disease burden worldwide than are other diseases, such as heart disease and cancer.[1] One out of every four U.S. adults has a mental illness and nearly 50 percent will develop at least one disorder during their lifetime.[2] Treating mental disorders is staggeringly expensive, costing an estimated $300 billion annually in the United States.[3] Mistreating or not treating these disorders carries substantial cost, as well, estimated at over $100 billion annually.[4] Undisclosed discontinuation of psychiatric medications may lead to unintended consequences including relapse, adverse events and hospitalizations.[5] 

 “As a mental health clinician, I understand that a high level of trust in the patient-provider relationship is the foundation for optimizing outcomes for my patients. Building on this foundation, I use self-report and behavioral assessments to personalize treatment plans for each of my patients,” said Luis Torres, M.D., Board Certified Psychiatrist, Advanced Behavioral Health, in Tavares, Fl. “With the combination  of UDT and PGT, I now have objective tools that I can combine into a comprehensive treatment strategy to provide enhanced care to patients with psychiatric disorders such as schizophrenia, depression, anxiety, bipolar disease, ADHD and substance use disorder.”

“Millennium is the leader in the field of solutions for providing personalized care,” said Millennium’s CEO, Brock Hardaway. “These new offerings for practitioners who prescribe psychiatric medications are a continuation of our commitment to improve the lives of patients by introducing new technologies and clinical tools. The objective information obtained with Millennium UDT and PGT can help clinicians move beyond the trial and error approach to treatment and better match patients with medications and treatment regimens most likely to provide the desired outcome.”

[1] World Health Organization. Promoting mental health: concepts, emerging evidence, practice: summary report. http://www.who.int/mental_health/evidence/en/promoting_mhh.pdf. Accessed September 10, 2013.

[2] Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.  Arch Gen Psych. 2005; 62 (7):768.

[3] Mark TL, Levit KR, Buck JA, et al. Mental health treatment expenditure trends, 1986-2003. Psychiatr Serv 2007;58:1041-8.

[4] National Alliance on Mental Illness. Mental Illnesses. http://www.nami.org/template.cfm?section=about_mental_illness. Accessed September 10, 2013.

[5] Mitchell AJ, Selmes T. Why don’t patients take their medicine? Reasons and solutions in psychiatry.  Advances in Psychiatric Treatment. 2007;13:336-46.

Contact: 
Nicole Beckstrand 
Corporate Communications 
Millennium Laboratories 
858-217-1192 
Nicole.Beckstrand@millenniumlabs.com

Millennium Laboratories Announces New Company Officers

Seasoned executives to help drive future performance and growth

SAN DIEGO (September 9, 2013) – Millennium Laboratories, a leader in the science of toxicology and pharmacogenetics, today announced  new company officers with proven successes in financial operations, information technology, and laboratory operations. The appointments will enable the company to continue to drive performance and prepare for expected growth. 

New appointments include:

 “All these new officers have a wealth of experience to help Millennium round out its executive team to meet strategic goals and seek new opportunities for growth,” said Brock Hardaway, CEO of Millennium Laboratories. “Individually and as a team, they will help us continue to deliver on the promise of better health care and outcomes for patients through a renewed focus on innovation.”

As the new chief financial officer, Timothy C. “Tim” Kennedy oversees all financial functions for Millennium Laboratories. Kennedy has more than 20 years of experience in financial operations and management in the health care industry, most recently as the chief financial officer and general manager of PLUS Diagnostics in New Jersey, a pathology laboratory specializing in urology and gastroenterology. Previously, Kennedy served as owner and CFO of Diagnostic Imaging Management, a magnetic resonance imaging provider, for more than 10 years. Kennedy also served as the vice president of finance and corporate controller at LabCorp. Kennedy received a bachelor’s degree in business, accounting and information systems from Kean University in New Jersey.

As the new chief operating officer, Mark A. Winham is responsible for the strategic planning and development of laboratory operations for Millennium Laboratories. Winham has nearly 30 years of laboratory and health care experience, and previously served as the vice president of global manufacturing at Life Technologies in Carlsbad, Calif. Winham holds a bachelor’s degree in life sciences from Napier University in Edinburgh, United Kingdom and a business diploma in company direction from the Institute of Directors in London.

As the new chief information officer, William W. “Bill” Zondler is responsible for the vision, strategy, and implementation of all aspects of information technology and telecommunications for the company. Zondler joins Millennium with more than 25 years of life sciences and commercial electronics manufacturing industry experience, and was most recently the vice president and chief information officer at Prometheus Laboratories, Inc. Zondler is a member of the San Diego Society for Information Management.

 

Contact:
Nicole Beckstrand
Corporate Communications
Millennium Laboratories
858-217-1192
Nicole.Beckstrand@millenniumlabs.com

Millennium Laboratories to Host Medication Monitoring Symposium at PAINWeek 2013

Symposium offers evidence to aid in enhanced personalized pain care

WHAT: Millennium Laboratories, the leading research-based clinical diagnostic company dedicated to improving the lives of people suffering from pain and addiction, will host a lunch symposium* entitled: A Case-Based Exploration in Medication Management: Using PGT and UDT to Enhance Care at PAINWeek, the largest pain conference for pain management clinicians, in Las Vegas on Thursday, Sept. 5.

WHO:

  • Jennifer Strickland, PharmD, vice president of clinical strategy, Millennium Laboratories (moderator)
  • Chris Herndon, PharmD, BCPS, CPE, Southern Illinois University School of Pharmacy, Ill.
  • Eric Ehlenberger, MD, Accurate Clinic, La.
  • Jeremy Adler, MS, PA-C, Pacific Pain Medicine Consultants, Calif.

Representatives from Millennium Laboratories will be available on site for media interviews. For more information, please visit Millennium Laboratories at booth #113.

WHY: The treatment of pain is complex and challenging, and often incorporates multiple medications and modalities. Clinical tools such as urine drug testing (UDT) and pharmacogenetic testing (PGT) offer objective information that aids in a more personalized approach to care.  This educational opportunity provides health care professionals with evidence emphasizing the clinical value of integrating pharmacogenetic testing (PGT) with urine drug testing (UDT) to enhance personalized pain care.

Millennium PGT is a saliva-based test designed to detect variations in enzymes associated with the metabolism of commonly prescribed medications. This tool can help clinicians personalize treatment and predict a patient’s genetically-driven response to certain medications. Millennium UDT utilizes Millennium’s proprietary methodologies and Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) technology to detect the presence of more than 375 brand name drugs from more than 80 parent drugs and metabolites. This highly specific and sensitive technology provides health care professionals with a quantitative measurement that is unaffected by other drugs or dietary supplements that may be present in the patient’s specimen.

WHO SHOULD ATTEND: Attendance is limited and available on a first come first served basis. Registered PAINWeek attendees may attend. Badge is required for entry.

WHEN: Thursday, September 5, 12:30-2:00 p.m.

WHERE: The Cosmopolitan of Las Vegas Brera Ballroom, 3708 S. Las Vegas Blvd., Las Vegas, NV 89109. PAINWeek attendee badge is required for entry.

 * This program does not offer CME/CE credit. This satellite symposium is neither sponsored nor endorsed by PAINWeek.

Contact:
Nicole Beckstrand
Corporate Communications
Millennium Laboratories
858-401-2897
Nicole.beckstrand@millenniumlabs.com

Heroes in Recovery Announces Second Annual Race in Louisville, Colorado

A Heroes in Recovery 6K Run/Walk event is taking place on July 13 to support those in recovery and break the stigma associated with addiction.

Nashville, TN (June 25, 2013)– Heroes in Recovery, a movement celebrating the heroic efforts of those who seek addiction and mental health treatment, is returning to Louisville, Colorado for one of its family-friendly 6K Run/Walk events. The goal of the race is to garner support for people in recovery and to educate the community at large about behavioral health issues. The Heroes in Recovery movement, ignited by Foundations Recovery Network (FRN), has been carried on the shoulders of supporters, advocates, friends, family members and all those touched by the disease of addiction.

Millennium Laboratories is the gold sponsor of the Heroes in Recovery 6K Run/Walk, which will be held on Saturday, July 13, at 8:00 a.m. at Louisville Community Park in Louisville, CO. The race will begin and end in the park, taking participants on a scenic 6K (3.728 mile) looping course around the park.

The race will include awards presented to the top three males and females in the overall category. Additional prizes will be awarded to the top three male and female finishers in their age divisions. Registered participants will each receive a short-sleeve technical t-shirt and finisher’s medal. This is a family-friendly event that will include food and entertainment for race participants and spectators.

The local charity beneficiary for this race is Phoenix Multisport, which fosters a supportive, physically active community for individuals who are recovering from alcohol and substance abuse and those who choose to live a sober life. Through such pursuits as climbing, hiking, running, swimming, road and mountain biking, and other activities, Phoenix Multiport seeks to help their members develop and maintain the emotional strength they need to stay sober.

This Heroes in Recovery event is the tenth race since 2011 in a series of 6K races being held across the country to raise awareness and destigmatize addiction treatment and recovery. Previous events have taken place in Nashville, TN, Palm Springs, CA, Louisville, CO, Greenville, SC, Memphis, TN, Roswell, GA, and Fort Lauderdale, FL.

Early registration for all races is $25, regular registration is $30, and day-of-race fees are $35.

For more information and to register, go to http://www.heroes6k.com.

About Heroes in Recovery:

According to the Substance Abuse and Mental Health Services Administration (SAMHSA), 20 million people needed substance abuse treatment last year and did not receive it. Ten million Americans did not receive needed mental health care. The stigma associated with substance abuse and mental health disorders creates a significant barrier to individuals and families seeking help.

Heroes in Recovery is a grassroots movement intended to remove the social stigma associated with people who are in recovery, to recognize the heroic effort it takes to overcome the obstacles in seeking help, and to celebrate the act of preventing the past from kidnapping the future. While the movement initially focuses on persons recovering from addictive behavior, it is also meant to recognize heroes recovering from mental health conditions that can feed or manifest from an addiction.

The Heroes in Recovery 6K races serve as an educational tool for communities as well as a reminder to individuals that while they are on a personal journey of recovery, many others are on that road with them. For more information or to register for any of the Heroes 6K races, go to HeroesInRecovery6K.com.

About Foundations Recovery Network:

Headquartered in Nashville, TN, Foundations Recovery Network is one of the premier organizations for treating those with co-occurring addiction and mental health disorders. FRN’s treatment facilities includes Michael’s House in Palm Springs, CA; The Canyon in Malibu, CA; La Paloma in Memphis, TN; and full-service outpatient treatment centers in Atlanta, GA; Santa Monica, CA; Memphis, TN; Nashville, TN; and Palm Springs, CA.

All FRN facilities utilize an integrated treatment approach, focusing on a Dual Diagnosis model for lasting recovery. http://www.foundationsrecoverynetwork.com

For general press information and media inquiries contact:

Jeff Skillen          
(615) 828-1950                  
jeff@skillsetenterprises.com

 

Millennium Laboratories Awarded U.S. Government Contracting Vehicle

Lab focused on pain and addiction medication monitoring can now serve active duty members and veterans

SAN DIEGO (June 24, 2013) – Millennium Laboratories, the leading research-based, clinical diagnostic company dedicated to improving the lives of people with chronic pain and addiction, announced today it was awarded a Federal Supply Schedule (FSS) government contracting vehicle effective June 1, 2013. After completing a multi-year application process and in recognition of its commitment to quality, Millennium Laboratories is now able to provide medication monitoring and detection services to federal agencies that serve the millions of veterans and active duty service members suffering from pain and addiction.

Appearing on the FSS contract enables businesses to offer their products and services to government entities. Millennium Laboratories’ test is designed to provide specific lab services focused on both pain management and addiction. Federal agencies, including Departments of Defense and Veterans Affairs, now have direct access to Millennium’s medication monitoring products and services to aid in the treatment of the unique polytrauma medical issues that the active duty and veteran populations face.

“Veterans often come back, after dedicating their lives to protecting our country, with devastating physical and psychological trauma. We want to be sure that the clinicians treating these heroes have the best drug monitoring technology and services available to treat them,” said Vice President, Global Defense Healthcare for Millennium Laboratories, Nancy Lazarski. “Our announcement today means that we are able to offer our expertise in drug monitoring to ease war-related trauma these individuals face.”

Millennium Laboratories utilizes LC-MS/MS technology with high sensitivity and specificity to identify more than 80 drugs and metabolites using a minimal volume (1-2mL useable urine) of specimen. This allows us to identify more than 375 brand name drugs patients may be taking. The comprehensive, quantified drug/metabolite specific results are delivered generally within one business day from receipt of specimen at the laboratory, giving healthcare professionals a clear picture of the medications and drugs their patients have used.

Contact:
Nicole Beckstrand
Sr. Director, Corporate Communications
858-217-1192
Nicole.beckstrand@millenniumlabs.com
 

 

Millennium Laboratories to Receive Award for Outstanding Support to Veteran Community and Employment


WHAT: The Patriot Group will be hosting “Hire a Patriot” Thursday, June 13, 2013 at The Commerce Hotel & Casino in Commerce, Calif. More than 55 exhibitors represent hundreds of job openings and educational opportunities for active duty service members, veterans and their families. Millennium Laboratories will also receive the inaugural “Above and Beyond the Call of Duty” award for its continued support to the veteran community.

WHO: The Patriot Group is committed to helping active duty military, veterans and their families transition and find meaningful employment, the right education or training and necessary resources. This event is sponsored by Millennium Laboratories, the leading research-based clinical diagnostic company dedicated to improving the lives of people suffering from pain and addiction. Nancy Lazarski, VP, Global Defense Health Care is available for media interviews on location.

WHY: People with military backgrounds have training, discipline, and team and leadership skills that make them extremely desirable candidates, yet, in 2012, the average unemployment rate for veterans was 9.9 percent, while the general population averaged 8.1 percent. And the unemployment rate for veterans aged 18-24 was as high as 30 percent two years ago, but dipped to 20 percent by the end of 2012. This event seeks to directly connect employers with these skilled individuals who are looking for new educational and career opportunities.

WHO SHOULD ATTEND: Active duty military, veterans and their family members who are seeking new educational and career opportunities should attend. The public is also welcome. Attendees should come dressed professionally and have plenty of copies of their resumes to hand out to the employers.

WHEN:  Thursday, June 13, 10 a.m. – 2 p.m.

  • • Presentation of the inaugural “Above and Beyond the Call of Duty” award to Millennium Laboratories’ Nancy Lazarski, VP, Global Defense Healthcare at 9:45 a.m.
  • • Special Guest Speaker—John Rixey Moore, former US Army Green Beret, actor, athlete and author from 9:50 a.m. – 10:00 a.m.
  • • Resume and Interview skills workshop, from 10:30 a.m. – 11:30 a.m. hosted by EDD
  • • “Job Ready Dress” –how to dress for success workshop from 12:30 p.m. – 1:30 p.m. hosted by Fashion Institute of Design & Merchandising (FIDM)

WHERE: The Commerce Hotel & Casino, 6131 East Telegraph Rd., Commerce, CA 90040. There is ample free self-parking.

 
Contact:

Nicole Beckstrand
Sr. Director, Corporate Communications
858-217-1192
Nicole.beckstrand@millenniumlabs.com


1 2 3 4


© 2013 Millennium Labs – Prescription Drug Monitoring & Genetic Testing, LLC. All rights reserved.